Maxime Teisseyre

Maxime Teisseyre

Auto-generated profile, based on publicly available information

Maxime Teisseyre

Centre Hospitalier Universitaire de Nice, Centre de Référence Maladies Rares Syndrome Néphrotique Idiopathique et Glomérulonéphirte Extra-Membraneuse

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2024 in Kidney International Reports
Verified
Journal Article
Open access
MCMarion Cremoni
Marion Cremoni
MTMaxime Teisseyre
Maxime Teisseyre
OTOlivier Thaunat
Olivier Thaunat
CFCéline Fernandez
Céline Fernandez
CPChristine Payre
Christine Payre
BSBarbara Seitz-Polski
Barbara Seitz-Polski
Membranous nephropathy can lead to end-stage kidney disease, for which kidney transplantation is the preferred therapy. However, the disease often relapses, which can impact allograft survival. We conducted a prospective multicenter study in France involving 72 patients with membranous nephropathy who were awaiting and then underwent kidney transplantation. In addition, we established a retrospective validation cohort of 65 patients. The primary objective was to evaluate the prognostic significance of pretransplant anti phospholipase A2 receptor 1 (PLA2R1) antibodies on the recurrence of membranous nephropathy. The study also assessed the incidence rate, time to onset, and risk factors for recurrence, as well as allograft outcome. The prospective cohort showed a 26% cumulative incidence of membranous nephropathy recurrence after a median follow-up of 23.5 months. This was confirmed by a 28% cumulative incidence after a median follow-up of 67 months in the retrospective cohort. A strong association was found between the presence of anti-PLA2R1 antibodies prior to transplantation and the risk of disease recurrence (risk ratio = 5.9; 95% confidence interval [CI]: 2.3–15.7; P < 0.0001). These results were confirmed in the retrospective cohort. Monitoring of anti-PLA2R1 antibodies in the immediate posttransplant period is of limited value, because recurrence occurred early in the first 6 months (median delay of 5 [3–14] months) after transplantation despite decreasing antibody levels. The presence of anti-PLA2R1 antibodies prior to transplantation was a strong predictor of recurrence of allograft membranous nephropathy. An individualized immunomonitoring and management strategy for kidney transplant candidates with anti-PLA2R1-associated membranous nephropathy should be considered.

2 April 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
MTMaxime Teisseyre
Maxime Teisseyre
ADAlexandre Destere
Alexandre Destere
MCMarion Cremoni
Marion Cremoni
KZKévin Zorzi
Kévin Zorzi
VBVesna Brglez
Vesna Brglez
BSBarbara Seitz-Polski
Barbara Seitz-Polski
Introduction Membranous nephropathy is an autoimmune kidney disease and the most common cause of nephrotic syndrome in non-diabetic Caucasian adults. Rituximab is now recommended as first-line therapy for membranous nephropathy. However, Kidney Disease Improving Global Outcomes guidelines do not recommend any specific protocol. Rituximab bioavailability is reduced in patients with membranous nephropathy due to urinary drug loss. Underdosing of rituximab is associated with treatment failure. We have previously developed a machine learning algorithm to predict the risk of underdosing. We have retrospectively shown that patients with a high risk of underdosing required higher doses of rituximab to achieve remission. The aim of this prospective study is to evaluate the efficacy of algorithm-driven rituximab treatment in patients with membranous nephropathy compared to standard treatment. Methods A multicentre, randomised, controlled, open-label, prospective superiority clinical trial will be conducted in 13 French hospitals. 130 consecutive patients with primary membranous nephropathy and active nephrotic syndrome will be randomised to either the standard protocol control group (two 1 g rituximab infusions on days 0 and 15) or the algorithm-driven rituximab treatment group. In the latter, the rituximab dose will depend on the algorithm-estimated risk of underdosing. Patients with an algorithm-estimated risk of underdosing ≤50% will receive 1 g of rituximab on days 0 and 15. Patients with an algorithm-estimated risk of underdosing between 51% and 75% will receive 1 g of rituximab on days 0, 15 and 30. Finally, patients with an estimated risk of underdosing >75% will receive 1 g of rituximab on days 0, 15, 30 and 45. The primary study outcome is the rate of clinical remission (complete or partial) at month 6 after treatment initiation. The secondary outcomes include clinical remission at month 12, immunological remission, proteinuria, albuminuria, serum creatinine, estimated glomerular filtration rate, phospholipase A2 receptor type 1 antibody titre, anti-rituximab antibody occurrence, lymphocyte count, serum rituximab level and related adverse events. Ethics and dissemination The trial received ethics approval from the local ethics boards. The results of this study will confirm whether algorithm-driven rituximab treatment is more effective in inducing remission than the standard regimen and thus may contribute to improving management of patients with membranous nephropathy. The results of our study will be submitted to a peer-review journal. Trial registration number NCT06341205 trial number. Registered on 2 April 2024.

5 November 2025 in La Revue de Médecine Interne
Verified
Journal Article
Open access
MTMaxime Teisseyre
Maxime Teisseyre
MAMarco Allinovi
Marco Allinovi
MLMichael Levraut
Michael Levraut
JLJacopo Lomi
Jacopo Lomi
MCMarion Cremoni
Marion Cremoni
BSBarbara Seitz-Polski
Barbara Seitz-Polski
Rituximab, a chimeric monoclonal antibody targeting the CD20, is a key therapy for treating haematological malignancies and numerous autoimmune diseases. However, its use may be complicated by the occurrence of anti-drug antibodies (ADA), which reflect its immunogenicity. This immunogenicity varies depending on the clinical context: it remains rare in oncology, but is more common in autoimmune diseases. These ADAs may be neutralising or non-neutralising and may influence pharmacokinetics, B-cell depletion, clinical efficacy and the risk of hypersensitivity reactions. Their occurrence is influenced by multiple factors: drug characteristics, administration methods, treatment regimen, but also patient-specific parameters. To limit immunogenicity, several approaches are being studied, such as optimising treatment regimens, combining with immunosuppressants, or using alternative humanised or fully human antibodies. This review provides an updated summary of anti-rituximab antibodies and highlights the importance of a personalised monitoring strategy to optimise the management of patients treated with rituximab.

13 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
MMMounir El Maï
Mounir El Maï
MTMaxime Teisseyre
Maxime Teisseyre
YCYousra Cheddadi
Yousra Cheddadi
VBVesna Brglez
Vesna Brglez
EVErendira Vazquez-Salazar
Erendira Vazquez-Salazar
BSBarbara Seitz-Polski
Barbara Seitz-Polski
Background: Membranous nephropathy (MN) is a chronic, autoimmune kidney disease characterized by an autoimmune response against podocyte-specific antigens, compromising renal functions. Few studies attempted to mechanistically describe how rituximab influences Th cells and whether this impacts on clinical outcome. Methods: Th cell profile of MN patients was characterized using peripheral blood mononuclear cell samples from a multi-centre, prospective clinical trial. Th cell subsets (Treg, Th17 and Th1) were measured by flow cytometry at baseline and after rituximab treatment during a two years follow-up. In vitro studies on fresh peripheral blood samples and isolated cell populations were performed to investigate the mechanisms through which rituximab induces Treg cells. Findings: Before rituximab treatment, MN patients had a Th17/Treg imbalance when compared to age-matched healthy donors (p=0.004). Responders had significantly higher proportions of Treg cells post-rituximab than non-responders (p=0.037). In vitro , rituximab treatment induced Treg cells when using peripheral blood samples from MN patients, however the induction was lost when isolated T cells were used instead of whole blood (p=0.02). Rituximab did not directly induce Treg cells but required a specific cellular environment composed by at least B and Natural Killer (NK) cells as observed by treating pooled T, B and NK cells. Finally, using complementation assays, we demonstrated that rituximab-mediated Treg induction relied on cytokines, mainly Transforming growth factor β (TGFβ), secreted by activated NK cells. Interpretation: Rituximab induces Treg through cytokines produced by NK cells probably during the mechanism of B cell depletion by antibody-dependent cell-mediated cytotoxicity. This mechanism could potentiate the likelihood of remission in MN patients by counteracting loss of immune tolerance.